Journal
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
Volume 70, Issue 5, Pages 1305-1309Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.ijrobp.2007.11.047
Keywords
brain metastases; radiosurgery; whole brain radiotherapy; quality of life; neurocognitive
Funding
- NCI NIH HHS [CA 25224] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [U10CA025224] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Brain metastases are common in cancer patients and cause considerable morbidity and mortality. For patients with limited disease and good performance status, treatment typically involves a combination of focal measures (e.g., surgical resection or radiosurgery) for the radiographically apparent disease, followed by adjuvant whole brain radiotherapy (WBRT) to treat subclinical disease. Because of concerns regarding the toxicity of WBRT, especially neurocognitive deterioration, many have advocated withholding adjuvant WBRT. Recently published studies have shed more light on the efficacy of adjuvant WBRT and the neurocognitive effects of WBRT. However, the inclusion of neurocognitive and quality-of-life data in clinical trials are still required to better define the role of adjuvant WBRT. Currently, two Phase III trials are underway, one in Europe and one in North America, that will determine the effect of adjuvant WBRT on patients' quality of life, neurocognitive function, and survival. (c) 2008 Elsevier Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available